ALBIREO PHARMA INC (ALBO)
US01345P1066 - Common Stock
ALBO gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. The financial health of ALBO is average, but there are quite some concerns on its profitability. ALBO shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
ALBO had negative earnings in the past year.
In the past year ALBO has reported a negative cash flow from operations.
ALBO had negative earnings in each of the past 5 years.
ALBO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
ALBO has negative profitability rations, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of ALBO (95.56%) is better than 95.92% of its industry peers.
ALBO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 95.56% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ALBO does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALBO has more shares outstanding than it did 1 year ago.
The debt/assets ratio for ALBO has been reduced compared to a year ago.
2.2 Solvency
ALBO has an Altman-Z score of 0.32. This is a bad value and indicates that ALBO is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ALBO (0.32) is comparable to the rest of the industry.
There is no outstanding debt for ALBO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.32 |
ROIC/WACCN/A
WACC9.04%
2.3 Liquidity
ALBO has a Current Ratio of 6.32. This indicates that ALBO is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ALBO (6.32) is comparable to the rest of the industry.
ALBO has a Quick Ratio of 6.23. This indicates that ALBO is financially healthy and has no problem in meeting its short term obligations.
ALBO has a Quick ratio (6.23) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.32 | ||
| Quick Ratio | 6.23 |
3. Growth
3.1 Past
ALBO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.52%, which is quite good.
The Revenue has grown by 432.29% in the past year. This is a very strong growth!
Measured over the past years, ALBO shows a very strong growth in Revenue. The Revenue has been growing by 47.13% on average per year.
EPS 1Y (TTM)10.52%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q4.95%
Revenue 1Y (TTM)432.29%
Revenue growth 3Y47.13%
Revenue growth 5YN/A
Revenue growth Q2Q168.34%
3.2 Future
ALBO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.17% yearly.
The Revenue is expected to grow by 84.10% on average over the next years. This is a very strong growth
EPS Next Y-20.91%
EPS Next 2Y0.48%
EPS Next 3Y13.05%
EPS Next 5Y24.17%
Revenue Next Year69.42%
Revenue Next 2Y72.94%
Revenue Next 3Y92.77%
Revenue Next 5Y84.1%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ALBO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALBO. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ALBO's earnings are expected to grow with 13.05% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.48%
EPS Next 3Y13.05%
5. Dividend
5.1 Amount
No dividends for ALBO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ALBIREO PHARMA INC
NASDAQ:ALBO (3/2/2023, 7:00:01 PM)
After market: 44.33 +0.18 (+0.41%)44.15
-0.1 (-0.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap915.89M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 95.56% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.18
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.32 | ||
| Quick Ratio | 6.23 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)10.52%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-20.91%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)432.29%
Revenue growth 3Y47.13%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y